BioCryst Receives Early Termination for Acquisition of Astria
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
BioCryst Pharmaceuticals (BCRX) has received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended with respect to BioCryst's proposed acquisition of Astria Therapeutics (ATXS). Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quarter of 2026, subject to other customary closing conditions.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ATXS with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ATXS
Wall Street analysts forecast ATXS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATXS is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
0 Buy
7 Hold
0 Sell
Hold
Current: 12.580
Low
13.00
Averages
13.00
High
13.00
Current: 12.580
Low
13.00
Averages
13.00
High
13.00
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halper Sadeh Investigates CSG and Others for Shareholder Rights Violations
- CSG Transaction Investigation: Halper Sadeh LLC is investigating CSG Systems International, Inc.'s sale to NEC Corporation for $80.70 per share in cash, potentially indicating breaches of fiduciary duties that could affect shareholder rights.
- Janus Transaction Scrutiny: The firm is also examining Janus Henderson Group plc's sale to Trian Fund Management and General Catalyst for $49.00 per share in cash, which may impact shareholder interests and rights.
- Clearwater Transaction Focus: Halper Sadeh is looking into Clearwater Analytics Holdings, Inc.'s sale to Permira and Warburg Pincus for $24.55 per share in cash, raising concerns about potential violations of shareholder rights.
- Astria Transaction Analysis: The firm is reviewing Astria Therapeutics, Inc.'s sale to BioCryst Pharmaceuticals, Inc. for $8.55 in cash and 0.59 shares of BioCryst common stock per share, which could affect the rights of Astria shareholders.
Continue Reading
Astria Therapeutics to be Sold to BioCryst for $8.55 per Share
- Transaction Investigation: Former Louisiana Attorney General Charles C. Foti and his law firm are investigating the proposed sale of Astria Therapeutics to BioCryst Pharmaceuticals, which involves a compensation of $8.55 in cash and 0.59 shares of BioCryst stock per Astria share, aiming to assess whether this deal undervalues the company.
- Shareholder Rights Concern: KSF is seeking to confirm the adequacy of the transaction process and compensation, emphasizing the importance of protecting shareholder rights by inviting those who believe the deal undervalues the company to discuss their legal options.
- Legal Consultation Services: KSF offers no-obligation legal consultations, encouraging shareholders to contact Managing Partner Lewis S. Kahn, which highlights the firm's commitment to shareholder interests and the pursuit of transaction transparency.
- Market Reaction Potential: The investigation into this transaction could impact shareholder confidence and market performance for Astria, as any findings of unfairness may lead to legal actions that could subsequently affect the company's stock price trajectory.
Continue Reading